BioSpace News Archive

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today preliminary results from two prospective studies demonstrated that AnPac Bio’s Cancer Differentiation Analysis (CDA) based tests have the ability to assess the risks of cancer occurrence. In a study of follow-up phone

- Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55 - EOP2 meeting scheduled for 29 th September, 2020 with FDA input expected in calendar Q4 2020 - Presented new preclinical data demonstrating the favorable safety profile and best-in-class potential of MDNA11 at ASCO 2020 - Depository Trust Certification (“DTC”) approved in July 2020 TORONTO and HOUSTON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Medicenna Th

Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the addition of four clinical trial sites to its ongoing AuroLase® pivotal study. T

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that members of management will present at three upcoming investor conferences in August: 2020 Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 11, 2020 Time: 11:30 a.m. ET BTIG Virtual Bio

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it will issue second quarter 2020 financial and operating results on Tuesday August 11, 2020 before the market opens. The Company will host an investor conference call that same day, August 11, at 10:00 a.m. Eastern Time, to discuss these results. To access the call live, please dial 416-406-0743 or 1-800-898-3989 and use

-- Financing to be Used for Advancement of Antibody Therapeutics to Treat Food and other Severe Allergies – -- Appoints Richard Boismenu, Ph.D., as Chief Scientific Officer – -- Derek Croote, Ph.D. Named as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- IgGenix, Inc, today announced it completed a $10 million Series A financing. The financing was led by Khosla Ventures with participation from Parker Ventur

Potential Collaboration in Diabetic Peripheral Neuropathy and Chemotherapy-Induced Peripheral Neuropathy for ASEAN Region

Pascal Biosciences Inc. is pleased to announce that its common shares were accepted for listing on the Frankfurt Stock Exchange under the trading symbol | ISIN: CA7024781089 | WKN: A2DQU4.

Sonnet BioTherapeutics Holdings, Inc. announced that it has signed warrant exercise and amendment agreements with existing institutional investors that are expected to provide the Company with gross proceeds of up to $10.5 million, while adjusting the shares underlying and removing the warrant share reset provisions from the Company’s outstanding Series B Warrants issued in April 2020.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Fang Ni, Pharm.D., as Chief Business Officer. “Fang’s proven track record in business development and corporate strategy, including his work as Black Diamond’s interim Chief Business Officer, gives us confidence that he has